China Medipharm Insights - Issue No. 33 - February 1999

 


Regular Price: USD 1,000

Special Price USD 700

30% OFF

* Required Fields

Regular Price: USD 1,000

Special Price USD 700

PAY BY INVOICE

Be the first to review this product

Table of Contents

China Medipharm Insights - Issue No. 33 - February 1999, CHINA MEDIPHARM INSIGHTSHOSPITAL DRUG CONSUMPTIONAnalysis of Drug Consumption in 10 Major Cities in ChinaAnalysis of Other Therapeutic CategoriesElectrolytesRespiratory Drugs and VitaminsAnti-Tumor DrugsPRODUCT NEWSCrystalline D-Ribose DevelopedPfizer’s Viagra into Phase II Clinical Trials in ChinarhIFN Approved for ProductionGW’s Lamivudine Approved For Treatment of HB in ChinaRecombinant Streptokinase ApprovedFujisawa to Launch Prograf in ChinaLukang’s Shapeilin Approved for ProductionHeptocarcinoma Targeting Drug DevelopedConba’s Taponin and Qian Lie Kang Enter US MarketA Drug for Allergic Rhinitis DevelopedBaobijia Approved for ProductionControlled Release Anti-Cancer Drugs DevelopedSquibb Launched a New Vitamin ProductTian Hai Kang Soft Capsule MarketedCOMPANY PROFILELei’s Pharmaceutical Co. Ltd. EstablishedXinhua and Lukang Merge into a ConglomerateQianjiang Pharma Becomes One of the LargestEye Drugs Production Centers in ChinaGeneleuk Biotechnology OperatedLukang’s Production Cost on Spiramycin Reduced by US$1.2 MillionSanming Agrochemical Acquired Sanming Pharmaceutical999 Group Disconnects Its Military TiesXiamen Jianfa Controlled Xiamen PharmaShijiazhuang Pharma Reports 155% Increase in ProfitHeart K Keeps Its Leading Position in Health Supplement SectorWuhan Tiantian Joins in Jianmin GroupLukang Expects Total Sales of US$114 Million for 1998Dongya Pharma Reports US$22.3 Million OutputShanghai Hanyin Reports 100% Increase in SalesXi’an Pharma Reports 76% Increase in Pretax ProfitNorth China Trademark Worth US$313.5 MillionXudong Haipu Set Goals for 1999Hebei Pharma Group Becomes One of the 50 Largest Ones in ChinaXinchang’s Rifampin Project AccomplishedChengdu Diao Reports US$72.3 Million Sales RevenueXi’an Cuisheng Purchased Three Pharma CompaniesBULK DRUG EXPORTAnalysis of Bulk Drug Exports at 84th Guangzhou Trade FairNEWS IN BRIEFSDA Assigned Drug Advertisement Evaluation ResponsibilitiesManagement on Imported Drugs to be TightenedGAP is to be Practiced in ChinaNew Heptocarcinoma Gene FoundShanghai Adverse Drug Reaction Center EstablishedMicrobe Genome Research Center in PlanDrug Trading Market Prohibited99’ National Drug Trade Fair Held in FuzhouZhejiang Develops Marine Drug IndustryHangzhou Provides Special Fund to Speed Up Bioengineering IndustryHenan Pharma Industry Reported 100% Increase in Profit7 Pharmaceutical Projects Won Prizes in JiangxiPeople in Shanghai Willing to Buy Medicines in Drug StoresHenan Unified Drug Purchasing from 1999First Servier Pharmaceutical Chemistry Prize Granted




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.